Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Overview of attention for article published in Frontiers in Pharmacology, January 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 20 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Aug 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Jul 2023

finerenone

Cited by Canadian Agency for Drugs and Technologies in Health on 18 May 2023

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.